ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
US Tech 100
18,064.80
0.02%
Dow Jones
38,686.32
1.51%
Brent Oil
81.295
0.00%
Bitcoin
67,587.95
0.16%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
06/01/20248:00AMBusiness WireMassive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
06/01/20248:00AMGlobeNewswire Inc.Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024NASDAQ:MOLNMolecular Partners AG
06/01/20248:00AMGlobeNewswire Inc.CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
06/01/20248:00AMBusiness WirePfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)NYSE:PFEPfizer Inc
06/01/20248:00AMBusiness WireKRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung CancerNYSE:BMYBristol Myers Squibb Co
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNYSE:RCUSArcus Biosciences Inc
06/01/20248:00AMGlobeNewswire Inc.Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
06/01/20248:00AMBusiness WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin LymphomaNYSE:PFEPfizer Inc
06/01/20248:00AMBusiness WireIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMANASDAQ:SMMTSummit Therapeutics Inc
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNYSE:RCUSArcus Biosciences Inc
06/01/20248:00AMBusiness WireAccutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
06/01/20248:00AMGlobeNewswire Inc.OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
06/01/20248:00AMGlobeNewswire Inc.Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic CancerNASDAQ:PPBTPurple Biotech Ltd
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
06/01/20248:00AMBusiness WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin LymphomaNYSE:TAKTakeda Pharmaceutical Company Ltd
06/01/20248:00AMGlobeNewswire Inc.Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial responseNASDAQ:IMCRImmunocore Holdings PLC
06/01/20248:00AMPR Newswire (US)Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual MeetingNYSE:LLYEli Lilly and Co
06/01/20248:00AMPR Newswire (US)BALEAF & SOJOS to host "Summer it up" summer fashion extravaganza!
06/01/20248:00AMPR Newswire (Canada)L'AMC souligne le Mois national de l'histoire autochtone
06/01/20248:00AMPR Newswire (US)WLR Automotive Group Celebrates Employee Philanthropy with Generous Donations
06/01/20248:00AMPR Newswire (US)Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse
06/01/20248:00AMPR Newswire (Canada)CMA reflects on National Indigenous History Month
06/01/20248:00AMPR Newswire (US)New Self-Help Book Empowers LGTBQ+ People, Parents, & Allies
06/01/20248:00AMPR Newswire (US)Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible patients
06/01/20248:00AMPR Newswire (US)James Avery Artisan Jewelry Opens New Store at Westover Marketplace
06/01/20248:00AMPR Newswire (US)TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting
06/01/20247:24AMPR Newswire (Canada)Le loyer étudiant moyen a augmenté de 20% en trois ans à Québec
06/01/20247:10AMPR Newswire (US)Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
06/01/20247:01AMGlobeNewswire Inc.Il documentario Life at the Yellow River Delta vince ai Telly Awards

Your Recent History

EU
SFIAH
Societe de Financement L...
USOTC
PHXCF
Phoenix Canada Oil (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved